Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

DiaSorin introduces primer pair for Candida auris

January 2020—DiaSorin Molecular has released a primer pair that targets Candida auris, for use in laboratory-developed molecular tests. Candida auris is often multidrug resistant and has caused recent outbreaks in hospitals and long-term care facilities across the U.S. and in more than 20 countries, the company reports. The primer pairs are classified as analyte-specific reagents, which can be used by high-complexity laboratories to develop their own LDTs. DiaSorin Molecular, 562-240-6500

FDA approves second drug to prevent HIV infection

January 2020—The FDA approved Descovy (emtrici­tabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35 kg (approximately 77 lbs.) for HIV-1 pre-exposure prophylaxis to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. (Descovy is not indicated in individuals at risk of HIV-1 infection from receptive vaginal sex, the company reports, because the effectiveness in this population has not been evaluated.)

FDA approves Myriad MyChoice CDx

January 2020—The FDA has approved Myriad Genetics’ MyChoice CDx for use as a companion diagnostic to identify women with advanced ovarian cancer who are candidates for Zejula (niraparib) in the late-line treatment setting. The FDA also approved the expanded use of Zejula (GlaxoSmithKline) for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency.

ChromaCode launches multidrug resistance assay

January 2020—ChromaCode has launched the HDPCR Multi-Drug Resistance (MDR) Panel, a highly multiplexed real-time PCR assay. The panel detects nine of the most common causes of Gram-negative multidrug resistance and toxigenic Clostridium difficile in a 96-well format. Key features of the panel, the company reports, include seamless integration onto common qPCR instrumentation, scalable throughput, and streamlined data analysis, management, and test customization with ChromaCode Cloud software. The MDR panel is for research use only.

Beckman Coulter acquires Cytobank

January 2020—Beckman Coulter Life Sciences announced its acquisition of Cytobank, a privately held, single-cell data analysis, software-as-a-service company based in Santa Clara, Calif.

Quansys Q-Plex technology

December 2019—Quansys Biosciences (Logan, Utah) announced that its Q-Plex technology has been selected as a featured innovation at the Geneva Health Forum in Switzerland, March 24–26, 2020.

DiaSorin VZV swab test gets CE mark

December 2019—DiaSorin Molecular received the CE mark for its Simplexa VZV Swab Direct assay. The molecular diagnostic test enables the direct detection of varicella-zoster virus DNA from cutaneous and mucocutaneous swab specimens.

Menarini launches MSBiosuite

December 2019—Menarini Silicon Biosystems launched MSBiosuite, a cloud-based solution that automates next-generation-sequencing data analysis for liquid biopsy and formalin-fixed, paraffin-embedded workflows. The solution, developed in partnership with BlueBee, provides NGS data processing, analysis, interpretation, and reporting for users of Menarini NGS library preparation kits. A clinical interpretation report is available optionally with the Ampli1 and DEPArray OncoSeek pipelines.

Nova Biomedical introduces electrolyte analyzer

December 2019—Nova Biomedical announced the release of its Stat Profile Prime ES Comp Plus. The analyzer offers a complete electrolyte profile, including ionized magnesium, and optional serial batch testing on whole blood, serum, or plasma.

CellaVision buys RAL Diagnostics

December 2019—On Oct. 1, CellaVision completed the acquisition of RAL Diagnostics (Martillac, France). RAL develops and sells products for sample preparation in hematology, microbiology, cytology, and pathology.

MARKETPLACE

TRENDING